2NDH image
Deposition Date 2016-05-27
Release Date 2017-05-31
Last Version Date 2024-05-15
Entry Detail
PDB ID:
2NDH
Keywords:
Title:
NMR solution structure of MAL/TIRAP TIR domain (C116A)
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Conformers Calculated:
20
Conformers Submitted:
20
Selection Criteria:
target function
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Toll/interleukin-1 receptor domain-containing adapter protein
Gene (Uniprot):TIRAP
Mutagens:C116A
Chain IDs:A
Chain Length:143
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling.
Proc. Natl. Acad. Sci. U.S.A. 114 E6480 E6489 (2017)
PMID: 28739909 DOI: 10.1073/pnas.1701868114

Abstact

MyD88 adaptor-like (MAL) is a critical protein in innate immunity, involved in signaling by several Toll-like receptors (TLRs), key pattern recognition receptors (PRRs). Crystal structures of MAL revealed a nontypical Toll/interleukin-1 receptor (TIR)-domain fold stabilized by two disulfide bridges. We therefore undertook a structural and functional analysis of the role of reactive cysteine residues in the protein. Under reducing conditions, the cysteines do not form disulfides, but under oxidizing conditions they are highly amenable to modification. The solution structure of the reduced form of the MAL TIR domain, determined by NMR spectroscopy, reveals a remarkable structural rearrangement compared with the disulfide-bonded structure, which includes the relocation of a β-strand and repositioning of the functionally important "BB-loop" region to a location more typical for TIR domains. Redox measurements by NMR further reveal that C91 has the highest redox potential of all cysteines in MAL. Indeed, mass spectrometry revealed that C91 undergoes glutathionylation in macrophages activated with the TLR4 ligand lipopolysaccharide (LPS). The C91A mutation limits MAL glutathionylation and acts as a dominant negative, blocking the interaction of MAL with its downstream target MyD88. The H92P mutation mimics the dominant-negative effects of the C91A mutation, presumably by preventing C91 glutathionylation. The MAL C91A and H92P mutants also display diminished degradation and interaction with interleukin-1 receptor-associated kinase 4 (IRAK4). We conclude that in the cell, MAL is not disulfide-bonded and requires glutathionylation of C91 for signaling.

Legend

Protein

Chemical

Disease

Primary Citation of related structures